Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.ABSTRACT Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HCV screening and treatment at a government‐run primary health centre (PHC) in Baldia Town, Karachi, Pakistan.
Sara Mazzilli +8 more
wiley +1 more source
Hepatitis C: global epidemiology and strategies for control [PDF]
, 2016 It is estimated that globally there are approximately 100 million persons with serological evidence of current or past HCV infection, and that HCV causes about 700 000 deaths each year.
Easterbrook, PJ +3 more
core
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme [PDF]
, 2019 To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale‐up of treatment among people who inject drugs (PWID).
Ahmad, Farsana +9 more
core +5 more sources
International Journal of Hepatology, Volume 2026, Issue 1, 2026.Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara +11 more
wiley +1 more source
Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs:A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment-ADVANCE HCV protocol study [PDF]
, 2019 Introduction: Hepatitis c is a blood-borne virus (HCV) that can seriously damage the liver and is spread mainly through blood-to-blood contact with an infected person.
Beer, Lewis J. Z. +8 more
core +2 more sources
International Journal of Hepatology, Volume 2026, Issue 1, 2026.Background Polypharmacy leads to drug–drug interactions (DDIs) with direct‐acting antivirals (DAAs). We quantified the DDI burden (Liverpool categories) and evaluated its association with effectiveness and safety. We assessed renal function as a predictor of adverse events (AEs) and reported loss to follow‐up (LTFU). Methods We retrospectively analyzed
Satoru Okabe +6 more
wiley +1 more source
Infectious Diseases and Therapy, 2020 Introduction Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings.
Masanori Atsukawa +42 more
doaj +1 more source
Efectividad y seguridad de daclatasvir/ sofosbuvir con o sin ribavirina en pacientes infectados por el genotipo 3 del virus de la hepatitis C: resultados en práctica clínica real [PDF]
, 2019 [Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients.
Castro-Iglesias, Ángeles +8 more
core +1 more source
HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype [PDF]
, 2019 The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA
Albillos, Agustín +27 more
core +2 more sources
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment : analysis of 5552 patients from 12 cohorts [PDF]
, 2020 Background and aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible.
Borgia S. M. +21 more
core +1 more source